» Articles » PMID: 16501577

CD30 is a Survival Factor and a Biomarker for Transformed Human Pluripotent Stem Cells

Abstract

The application of human embryonic stem (hES) cells in regenerative medicine will require rigorous quality control measures to ensure the safety of hES cell-derived grafts. During propagation in vitro, hES cells can acquire cytogenetic abnormalities as well as submicroscopic genetic lesions, such as small amplifications or deletions. Many of the genetic abnormalities that arise in hES cell cultures are also implicated in human cancer development. The causes of genetic instability of hES cells in culture are poorly understood, and commonly used cytogenetic methods for detection of abnormal cells are capable only of low-throughput analysis on small numbers of cells. The identification of biomarkers of genetic instability in hES cells would greatly facilitate the development of culture methods that preserve genomic integrity. Here we show that CD30, a member of the tumor necrosis factor receptor superfamily, is expressed on transformed but not normal hES cells, and that CD30 expression protects hES cells against apoptosis.

Citing Articles

Gain of 1q confers an MDM4-driven growth advantage to undifferentiated and differentiating hESC while altering their differentiation capacity.

Krivec N, Couvreu de Deckersberg E, Lei Y, Al Delbany D, Regin M, Verhulst S Cell Death Dis. 2024; 15(11):852.

PMID: 39572522 PMC: 11582570. DOI: 10.1038/s41419-024-07236-x.


Longitudinal analysis of genetic and epigenetic changes in human pluripotent stem cells in the landscape of culture-induced abnormality.

Kim Y, Kang B, Kweon S, Oh S, Kim D, Gil D Exp Mol Med. 2024; 56(11):2409-2422.

PMID: 39482531 PMC: 11612254. DOI: 10.1038/s12276-024-01334-8.


Gains of 20q11.21 in human pluripotent stem cells: Insights from cancer research.

Krivec N, Ghosh M, Spits C Stem Cell Reports. 2023; 19(1):11-27.

PMID: 38157850 PMC: 10828824. DOI: 10.1016/j.stemcr.2023.11.013.


Characterization of human induced pluripotent stems cells: Current approaches, challenges, and future solutions.

Babu S, Duvvuru H, Baker J, Switalski S, Shafa M, Panchalingam K Biotechnol Rep (Amst). 2023; 37:e00784.

PMID: 36818379 PMC: 9929203. DOI: 10.1016/j.btre.2023.e00784.


The Impact of Acquired Genetic Abnormalities on the Clinical Translation of Human Pluripotent Stem Cells.

Keller A, Spits C Cells. 2021; 10(11).

PMID: 34831467 PMC: 8625075. DOI: 10.3390/cells10113246.